Christopher S. Little
Philadelphia College of Osteopathic Medicine
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Christopher S. Little.
Journal of Neuroscience Research | 2003
Angela MacIntyre; R. Abramov; Christine J. Hammond; Alan P. Hudson; E.J. Arking; Christopher S. Little; Denah M. Appelt; Brian J. Balin
We have investigated the effects of Chlamydia pneumoniae on human brain endothelial cells (HBMECs) and human monocytes as a mechanism for breaching the blood‐brain barrier (BBB) in Alzheimers disease (AD). HBMECs and peripheral blood monocytes may be key components in controlling the entry of C. pneumoniae into the human brain. Our results indicate that C. pneumoniae infects blood vessels and monocytes in AD brain tissues compared with normal brain tissue. C. pneumoniae infection stimulates transendothelial entry of monocytes through HBMECs. This entry is facilitated by the up‐regulation of VCAM‐1 and ICAM‐1 on HBMECs and a corresponding increase of LFA‐1, VLA‐4, and MAC‐1 on monocytes. C. pneumoniae infection in HBMECs and THP‐1 monocytes up‐regulates monocyte transmigration threefold in an in vitro brain endothelial monolayer. In this way, C. pneumoniae infection in these cell types may contribute to increased monocyte migration and promote inflammation within the CNS resulting from infection at the level of the vasculature. Thus, infection at the level of the vasculature may be a key initiating factor in the pathogenesis of neurodegenerative diseases such as sporadic AD.
Infection and Immunity | 2005
Christopher S. Little; Andrew Bowe; Richard Lin; Jason Litsky; Robert M Fogel; Brian J. Balin; Kerin L. Fresa-Dillon
ABSTRACT The intracellular bacterium Chlamydophila (“Chlamydia”) pneumoniae is a pathogen for several respiratory diseases and may be a factor in the pathogenesis of chronic diseases of aging including atherosclerosis and Alzheimers disease. We assessed whether aging is coupled with increased burden of infection in BALB/c mice after intranasal infection by C. pneumoniae. Six- and twenty-month-old BALB/c mice were infected intranasally with 5 × 104 inclusion forming units (IFU) or 5 × 105 IFU of C. pneumoniae. Lung, brain, and heart tissue were analyzed for infectious C. pneumoniae and for Chlamydophila antigen by immunohistochemistry. At both doses, aging was associated with a decreased proportion of animals that cleared infection from the lung and greater burden of infectious organism within the lung. We observed dose-dependent spread to the heart/ascending aorta in animals infected with C. pneumoniae. In mice given 5 × 104 IFU, spread to the heart by day 14 was only observed in old mice. By day 28, all animals inoculated with 5 × 104 IFU showed evidence of spread to the heart, although higher C. pneumoniae titers were observed in the hearts from old mice. In mice inoculated with 5 × 105 IFU, spread of C. pneumoniae to the heart was evident by day 14, with no discernible age effect. C. pneumoniae was also recovered from the central nervous system (brain and olfactory bulb) of all mice by day 28 postinfection, with higher C. pneumoniae titers in old animals than in young animals. Our results suggest that infection with C. pneumoniae may be more severe in old animals.
Frontiers in Aging Neuroscience | 2014
Christopher S. Little; Timothy Joyce; Christine J. Hammond; Hazem Matta; David Cahn; Denah M. Appelt; Brian J. Balin
Pathology consistent with that observed in Alzheimer’s disease (AD) has previously been documented following intranasal infection of normal wild-type mice with Chlamydia pneumoniae (Cpn) isolated from an AD brain (96-41). In the current study, BALB/c mice were intranasally infected with a laboratory strain of Cpn, AR-39, and brain and olfactory bulbs were obtained at 1–4 months post-infection (pi). Immunohistochemistry for amyloid beta or Cpn antigens was performed on sections from brains of infected or mock-infected mice. Chlamydia-specific immunolabeling was identified in olfactory bulb tissues and in cerebrum of AR-39 infected mice. The Cpn specific labeling was most prominent at 1 month pi and the greatest burden of amyloid deposition was noted at 2 months pi, whereas both decreased at 3 and 4 months. Viable Cpn was recovered from olfactory bulbs of 3 of 3 experimentally infected mice at 1 and 3 months pi, and in 2 of 3 mice at 4 months pi. In contrast, in cortical tissues of infected mice at 1 and 4 months pi no viable organism was obtained. At 3 months pi, only 1 of 3 mice had a measurable burden of viable Cpn from the cortical tissues. Mock-infected mice (0 of 3) had no detectable Cpn in either olfactory bulbs or cortical tissues. These data indicate that the AR-39 isolate of Cpn establishes a limited infection predominantly in the olfactory bulbs of BALB/c mice. Although infection with the laboratory strain of Cpn promotes deposition of amyloid beta, this appears to resolve following reduction of the Cpn antigen burden over time. Our data suggest that infection with the AR-39 laboratory isolate of Cpn results in a different course of amyloid beta deposition and ultimate resolution than that observed following infection with the human AD-brain Cpn isolate, 96-41. These data further support that there may be differences, possibly in virulence factors, between Cpn isolates in the generation of sustainable AD pathology.
Frontiers in Aging Neuroscience | 2018
Brian J. Balin; Christine J. Hammond; Christopher S. Little; Susan T. Hingley; Zein Al-Atrache; Denah M. Appelt; Judith A. Whittum-Hudson; Alan P. Hudson
The disease known as late-onset Alzheimer’s disease is a neurodegenerative condition recognized as the single most commonform of senile dementia. The condition is sporadic and has been attributed to neuronal damage and loss, both of which have been linked to the accumulation of protein deposits in the brain. Significant progress has been made over the past two decades regarding our overall understanding of the apparently pathogenic entities that arise in the affected brain, both for early-onset disease, which constitutes approximately 5% of all cases, as well as late-onset disease, which constitutes the remainder of cases. Observable neuropathology includes: neurofibrillary tangles, neuropil threads, neuritic senile plaques and often deposits of amyloid around the cerebrovasculature. Although many studies have provided a relatively detailed knowledge of these putatively pathogenic entities, understanding of the events that initiate and support the biological processes generating them and the subsequent observable neuropathology and neurodegeneration remain limited. This is especially true in the case of late-onset disease. Although early-onset Alzheimer’s disease has been shown conclusively to have genetic roots, the detailed etiologic initiation of late-onset disease without such genetic origins has remained elusive. Over the last 15 years, current and ongoing work has implicated infection in the etiology and pathogenesis of late-onset dementia. Infectious agents reported to be associated with disease initiation are various, including several viruses and pathogenic bacterial species. We have reported extensively regarding an association between late-onset disease and infection with the intracellular bacterial pathogen Chlamydia pneumoniae. In this article, we review previously published data and recent results that support involvement of this unusual respiratory pathogen in disease induction and development. We further suggest several areas for future research that should elucidate details relating to those processes, and we argue for a change in the designation of the disease based on increased understanding of its clinical attributes.
Journal of Alzheimer's Disease | 2008
Brian J. Balin; Christopher S. Little; Christine J. Hammond; Denah M. Appelt; Judith A. Whittum-Hudson; Hervé C. Gérard; Alan P. Hudson
Alzheimer's disease: New advances | 2006
Christine J. Hammond; Christopher S. Little; N. Longo; C. Procacci; Denah M. Appelt; Brian J. Balin
Neurobiology of Aging | 2004
Christopher S. Little; Christine J. Hammond; Denah M. Appelt; Brian J. Balin
Neurobiology of Aging | 2004
Brian J. Balin; Michelle Lee; Christine J. Hammond; Sheryl Patel; Angela MacIntyre; Christopher S. Little; Denah M. Appelt
Neurobiology of Aging | 2004
Denah M. Appelt; Maria Roupas; Christine J. Hammond; Christopher S. Little; Brian J. Balin
Archive | 2017
Brian J. Balin; Christine J. Hammond; Christopher S. Little; Susan T. Hingley; Denah M. Appelt; Judith A. Whittum-Hudson; Hervé C. Gérard; Alan P. Hudson